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Abstract
Cardiac autonomic neuropathy (CAN) is a frequent 
chronic complication of diabetes mellitus with potentially 
life-threatening outcomes. CAN is caused by the 
impairment of the autonomic nerve fibers regulating 
heart rate, cardiac output, myocardial contractility, cardiac 
electrophysiology and blood vessel constriction and 
dilatation. It causes a wide range of cardiac disorders, 
including resting tachycardia, arrhythmias, intraoperative 
cardiovascular instability, asymptomatic myocardial 
ischemia and infarction and increased rate of mortality 
after myocardial infarction. Etiological factors associated 
with autonomic neuropathy include insufficient glycemic 
control, a longer period since the onset of diabetes, 
increased age, female sex and greater body mass index. 
The most commonly used methods for the diagnosis 
of CAN are based upon the assessment of heart rate 
variability (the physiological variation in the time interval 
between heartbeats), as it is one of the first findings in 
both clinically asymptomatic and symptomatic patients. 
Clinical symptoms associated with CAN generally occur 
late in the disease process and include early fatigue and 
exhaustion during exercise, orthostatic hypotension, 
dizziness, presyncope and syncope. Treatment is based 
on early diagnosis, life style changes, optimization of 
glycemic control and management of cardiovascular risk 
factors. Medical therapies, including aldose reductase 
inhibitors, angiotensin-converting enzyme inhibitors, 
prostoglandin analogs and alpha-lipoic acid, have been 
found to be effective in randomized controlled trials. 
The following article includes the epidemiology, clinical 
findings and cardiovascular consequences, diagnosis, 
and approaches to prevention and treatment of CAN.
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Core tip: Although very frequent, cardiac autonomic 
neuropathy (CAN) is one of the most commonly 
overlooked complication of diabetes. Higher incidence 
of cardiovascular events is encountered with CAN 
due to its relation with silent myocardial ischemia, 
arrhythmias, intraoperative cardiovascular instability, 
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orthostatic hypotension and cardiomyopathy. Diabetic 
patients should be screened for CAN due to the 
possibility of reversal of cardiovascular denervation in 
the early stages of the disease. Cardiovascular reflex 
tests and Holter-derived time- and frequency-domain 
measurements are frequently used for the diagnosis. 
Therapeutic approaches are promising and may hinder 
or reverse the progression of the disease when initiated 
during the early stages. 
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INTRODUCTION
Cardiac autonomic neuropathy (CAN), a type of  gene-
ralized symmetric polyneuropathy, is the most examined 
and clinically significant diabetic autonomic neuropathy[1]. 
The autonomic nervous system has 2 major components: 
the parasympathetic and the sympathetic nervous 
systems. These may operate independently of  each other 
or interact cooperatively to control heart rate, cardiac 
output, myocardial contractility, cardiac electrophysiology, 
and the constriction and dilatation of  blood vessels[2]. 
CAN is caused by damage to the autonomic nerve fibers 
that innervate the heart and blood vessels and leads to 
abnormalities in cardiovascular dynamics[2]. The earliest 
finding of  CAN, even at the subclinical stage, is a decrease 
in heart rate variability (HRV)[3]. 
EPIDEMIOLOGY
Diabetes is estimated to affect approximately 350 million 
people globally[4]. Diabetic neuropathies, including 
CAN, are frequent chronic complications of  type 1 
and 2 diabetes that influence quality of  life and have 
potentially fatal outcomes[2]. Prevalence rates between 
1.6% to 90% have been reported, varying according to 
the diagnostic methods used, population studied and 
disease stage[1]. The Diabetes Control and Complications 
Trial (DCCT) showed abnormal HRV values of  1.65%, 
6.2% and 12.2% in patients with diabetes for a duration 
of  less than 5 years, 5 to 9 years and more than 9 years, 
respectively[5]. A study including 1171 patients with both 
type of  diabetes mellitus reported impaired HRV tests 
in 25.3% of  type 1 and 34.3% of  type 2 patients[6]. The 
different methodology between various studies makes 
epidemiological comparison difficult. Risk factors of  
decreased HRV in patients with type 2 diabetes include 
age, duration of  diabetes, obesity and smoking[2]. In type 
1 diabetes, risk factors of  CAN include higher levels of  
HbA1c, hypertension, distal symmetrical polyneuropathy, 
retinopathy and hyperglycemic exposure[7,8].
PATHOGENESIS
Diabetic CAN is eventually caused by complex inter-
actions among a number of  pathogenic pathways. 
Hyperglycemia is the leading cause of  the initiation of  
this pathogenic process[9,10]. The pathogenesis of  diabetic 
CAN is multifactorial, including increased mitochondrial 
production of  free radicals due to hyperglycemia-induced 
oxidative stress. Neuronal activity, mitochondrial function, 
membrane permeability and endothelial function are 
impacted by advanced glycosylation end product formation, 
polyol aldose reductase signaling and poly(ADP ribose) 
polymerase activation and the alteration of  the Na+/K+-
ATPase pump function. Neuronal apoptotic processes 
are precipitated by endoplasmic reticulum stress induced 
by hyperglycemia, along with impaired nerve perfusion, 
dyslipidemia, alterations in redox status, low-grade 
inflammation and disturbance in calcium balance[11]. 
The literature has described these mechanisms and their 
interactions but is beyond the scope of  this article[9-11]. 
CLINICAL MANIFESTATIONS
Diabetes can lead to dysfunction in the autonomic nervous 
system, causing various cardiovascular disorders, including 
resting tachycardia, postural hypotension, higher intra/
perioperative cardiovascular instability, more frequent 
asymptomatic myocardial ischemia and infarction, and 
greater mortality after myocardial infarction[2]. Clinical 
symptoms associated with CAN generally occur at 
later stages and include postural hypotension, dizziness, 
lightheadedness, presyncope, syncope, and early fatigue 
and exhaustion during exercise[1]. However, subclinical 
autonomic dysfunction, revealed as deterioration in HRV, 
can occur in the 1st year following diagnosis in patients with 
type 2 diabetes and within 2 years following diagnosis in 
type 1[12]. Low et al[13] reported a higher rate of  autonomic 
symptoms in type 1 than in type 2 diabetes. A greater 
number of  autonomic symptoms have been associated with 
an increased risk of  CAN as measured by HRV[14]. 
Because neuropathy first affects the longest nerve 
fibers, the first manifestation of  diabetic CAN tends to 
be related with vagus nerve damage, which is responsible 
for nearly 75% of  parasympathetic activity[9]. This 
damage causes resting tachycardia as the sympathetic tone 
becomes dominant[15]. Tachycardia eventually diminishes 
in a few years due to progressive sympathetic nerve fiber 
damage. However, increased heart rate persists in these 
patients[16]. The progressive damage of  the autonomic 
balance is indicated by additional symptoms, including 
intolerance to exercise, orthostatic hypotension and a 
further HRV reduction[17]. Cardiac pain perception often 
deteriorates with the involvement of  sensory nerve fibers, 
making patients prone to silent ischemia and myocardial 
infarction[18,19].  
Etiological factors associated with autonomic neu-
ropathy include poor glycemic control, longer diabetes 
duration, increased age, female sex and greater body 
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mass index[20]. Mortality rates of  25% to 50% within 5 to 
10 years of  diagnosis have been found in patients with 
symptomatic autonomic dysfunction[21,22]. Among diabetic 
patients, the 5-year mortality rate is 3 times higher in those 
with autonomic involvement than in those without[23]. 
CARDIOVASCULAR CONSEQUENCES
Impaired heart rate variability
HRV is a physiological variation in the interval between 
heartbeats and is regulated by the interaction of  the 
sympathetic and parasympathetic tone[24]. The functional 
response to the instantaneous metabolic needs of  the 
body is regulated by this beat-to-beat variation. As high 
variability reflects the cardiac ability to adapt and implies 
good health, damage or disturbances to this control 
system results in lower HRV values. Even in a normal 
heart rate, the first finding of  CAN is a decrease in HRV, 
which is apparent at the subclinical stage and can be 
detected through deep respiration[25]. 
Resting tachycardia
Due to the dominant sympathetic tone, resting heart 
rates of  90 to 100 beats per minute with occasional 
increases to as many as 130 beats per minute are frequent 
findings in CAN with vagal impairment[16,26]. Highest 
resting heart rates have been shown in patients with lone 
parasympathetic impairment[16,26]. As the disease progresses 
and involves both parasympathetic and sympathetic 
nerves, the heart rate tends to return to the normal range 
but remains higher than in healthy individuals[16,26]. Tang 
et al[27] showed that resting heart rate is independently 
associated with CAN and has a high predictive value in 
predicting CAN in the general population[27]. A steady 
heart rate less responsive to exercise, stress or sleep is 
suggestive of  almost total cardiac denervation, which 
indicates severe CAN[20]. 
Exercise intolerance
Exercise tolerance is worsened by CAN through the 
blunting of  the increases in heart rate, blood pressure and 
cardiac output response to exertion[20]. The development 
of  hypotension or hypertension following strenuous 
exercise is more likely in individuals with CAN, particularly 
in the onset of  a new exercise program[1]. Therefore, 
patients with diabetes probably to have CAN should be 
checked for cardiac stress before beginning to exercise[1]. 
Due to poor thermoregulation, such patients should avoid 
exercising in environments that are too hot or cold and 
hydrate adequately[1].
Intraoperative and perioperative cardiovascular 
instability
The perioperative risk of  cardiovascular morbidity and 
mortality are 2 to 3 times higher in diabetic individuals[28]. 
Since the normal autonomic response of  vasoconstriction 
and the increase in heart rate cannot appropriately com-
pensate for the vasodilatation and negative chronotropic 
effects of  anesthesia, diabetic patients with CAN are 
subject to more pronounced decreases in blood pressure 
and heart rate during induction of  anesthesia and, to 
a lesser extent, after intubation and extubation[20,28]. In 
addition, more severe intraoperative hypothermia in 
patients with CAN resulting in decelerated metabolism of  
anesthetic drugs may cause deepening of  anesthesia and/
or delayed recovery[29]. Accordingly, screening for CAN 
is recommended during the preoperative evaluation of  
diabetic patients for anesthetic management planning.
Non-dipping blood pressure profile and orthostatic 
hypotension
Blood pressure has diurnal variations. Decreases in 
nighttime and increases in daytime blood pressure show 
its circadian rhythm[30]. Declines in parasympathetic tone 
occur at night and nocturnal unopposed sympathetic 
activity leads to deterioration of  the circadian rhythm 
of  blood pressure and results in the lack of  or a less 
than 10% reduction in nocturnal blood pressure in 
patients with CAN[31].  Such “non-dipper” CAN subjects 
experience more frequent left ventricular hypertrophy 
and are predisposed to cardiovascular events[32].  Another 
blood pressure regulation abnormality related to CAN is 
orthostatic hypotension, which is defined as a decrease 
in systolic blood pressure by a minimum of  20 mmHg 
(at least 30 mmHg in patients with hypertension) or 
diastolic blood pressure of  10 mmHg in response to 
postural shifts from the supine to the standing[2,20]. In 
diabetic individuals, orthostatic hypotension develops as a 
consequence of  denervation of  the efferent sympathetic 
vasomotor nerves, especially in the splanchnic vascular 
bed[33]. Additionally, pathogenesis of  orthostatic hypo-
tension includes lower cutaneous, splanchnic and total 
vascular resistance[10]. Impaired chronotropic and/or 
blood pressure response to exercise may accompany this 
condition[10]. Orthostatic hypotension can cause many 
symptoms that reduce quality of  life or lead to serious 
injury due to falling, such as lightheadedness, dizziness, 
faintness, visual blurring, presyncope and syncope while 
standing[20]. However, an important number of  patients 
are asymptomatic despite significant decreases in blood 
pressure[2]. Orthostatic hypotension can be provoked 
by several drugs, which may be used concurrently for 
treatment of  diabetes or its complications, including, 
vasodilators, diuretics, phenothiazines, insulin (through 
endothelium-dependent vasodilation) and tricyclic 
antidepressants for symptomatic relief  of  pain associated 
with diabetic neuropathy[9].  
Silent myocardial ischemia
Coronary artery disease has long been considered as a 
major complication of  diabetes mellitus[34]. Numerous 
studies have reported more extensive atherosclerotic 
disease, particularly that of  the coronary arteries, in 
diabetic individuals[35,36]. Silent myocardial ischemia is 
defined as the objective documentation of  myocardial 
ischemia without angina or its equivalents[37]. Several 
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Sudden death
CAN is associated with a higher risk of  malignant 
arrhythmias and sudden death[9]. Previous studies have 
found 5-year mortality rates between 16% and 50% in 
patients with both CAN and either type of  diabetes, often 
attributed to sudden cardiac death[14,23]. Severe asymptomatic 
ischemia inducing fatal arrhythmias has been reported as 
the leading potential cause[22]. Additionally, life-threatening 
arrhythmias and sudden death may be predisposed by 
QT prolongation[52]. The European Diabetes Insulin-
Dependent Diabetes Mellitus (EURODIAB IDDM) 
Complications Study established the association between 
impaired HRV and corrected QT prolongation[53]. In 
addition, unopposed increases in sympathetic activity 
and resultant norepinephrine signaling and metabolism[9], 
along with increased mitochondrial oxidative stress[54] and 
calcium-dependent apoptosis[55], is thought to contribute 
to myocardial injury[54,56] and clarify the higher risk of  
sudden cardiac events and deaths. The EURODIAB 
IDDM Prospective Cohort Study, including 2787 patients 
with type 1 diabetes, reported CAN to be the strongest 
predictor of  mortality over the 7-year follow-up period, 
even greater than traditional cardiovascular risk factors[57]. 
A meta-analysis including 15 studies and 2900 diabetic 
patients showed CAN patients to have a pooled relative 
risk of  mortality of  3.45 (95%CI: 2.66-4.47) and an 
increase in line with higher numbers of  cardiovascular 
autonomic function abnormalities[58]. Similar results were 
confirmed in 2 other studies of  patients with type 1 
and type 2 diabetes, strengthening the role in predicting 
mortality of  abnormalities in both HRV and the QT index 
independent of  conventional risk factors[59,60]. The Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) 
trial[61] also confirmed the association between CAN and 
mortality in type 2 diabetic patients. In this trial, Pop-
Busui et al[62] showed that mortality was between 1.55 
and 2.14 times more likely in patients with baseline CAN 
than those without[62]. Three large studies (the ACCORD 
trial[61], the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled 
Evaluation trial[63], and the Veterans Affairs Diabetes 
Trial[64]) investigated the role of  more intensive treatment 
and the frequency of  cardiovascular events on individuals 
with long-term type 2 diabetes. In these trials, tight 
glycemic control was not shown to reduce cardiovascular 
adverse events[2] and the ACCORD trial was terminated 
early due to the increased mortality risk in the intensive 
therapy group[65]. Hypoglycemia is known to reduce the 
threshold for malignant ventricular arrhythmias that can 
result in sudden death[9,66]. In addition, hypoglycemic 
periods were reported to lead to impaired autonomic 
cardiovascular function even in healthy volunteers[67]. 
Hence, the cause of  a lack of  a decrease, or even an 
increase, in cardiovascular events in the intensive therapy 
arm may be linked to deterioration of  cardiac autonomic 
function due to episodes of  hypoglycemia. 
Cardiomyopathy
Diabetic cardiomyopathy is defined as structural and 
reports have shown the predictive role of  silent ischemia 
during exercise testing[38] or ambulatory electrocardiography 
(ECG) monitoring[39] on poor clinical outcomes and 
survival. A threefold increase in cardiac deaths was 
witnessed over a 2-year follow-up in individuals with 
silent ischemia during ambulatory ECG monitoring[39]. 
Painless presentation of  myocardial infarction in 
patients with CAN may include diaphoresis, dyspnea, 
fatigue, lightheadedness, palpitations, acute confusion, 
indigestion, nausea, and vomiting[20]. Several explanations 
are possible for the variety of  symptom patterns in 
individuals with diabetes, such as various pain perception 
thresholds, sensorial denervation secondary to autonomic 
neuropathy and psychological disavowal[34]. Therefore, 
despite increasing ischemia, individuals with CAN and 
coronary artery disease may resume exercise as the longer 
threshold or subthreshold ischemia is not sufficient to 
induce pain, thus endangering the patient[40]. Likewise, the 
Framingham Heart Study reported higher incidences of  
painless myocardial infarction in patients with diabetes 
than without (39% vs 22%)[41,42]. Similarly, the National 
Registry of  Myocardial Infarction 2 (NRMI-2) survey 
found that one-third of  patients presented without 
angina[43]. In the NRMI-2, diabetes was present in 32% 
of  subjects without chest pain and 25.4% with angina[43]. 
The Detection of  Ischemia in Asymptomatic Diabetic 
Study, including 1123 patients with type 2 diabetes, 
reported that CAN is able to strongly predict silent 
ischemia and succeeding adverse cardiovascular events[44]. 
Vinik et al[10], in their meta-analysis of  12 studies, reported 
the association between CAN and the existence of  silent 
ischemia detected by exercise stress tests with prevalence 
rate ratios of  0.85 to 15.53[10]. Therefore, patients with 
CAN require more rigorous evaluation of  the presence 
of  coronary artery disease. The presence and extent of  
macrovascular coronary artery disease in such patients 
can be noninvasively tested by resting and stress thallium 
myocardial scintigraphy[1]. Moreover, cardiovascular 
autonomic function testing should be included in the 
coronary artery risk assessment of  all diabetic patients.
Myocardial infarction and increased risk of mortality
Myocardial infarction tends to be more extensive and 
severe in patients with diabetes[42,45]. The timely diagnosis 
of  myocardial ischemia or infarction is often delayed due 
to diminished angina perception and therefore the period 
before first medical contact is prolonged[46]. Long-term 
survival rates following acute myocardial infarction are 
lower in patients with diabetes[20]. In diabetic patients, 
5-year survival rates of  38% have been reported following 
the first major coronary event, lowering to just 25% for 
those with subsequent events, while the rates are 75% 
and 50%, respectively, in non-diabetic patients[45,47]. HRV 
has been demonstrated to be a good predictor of  post-
myocardial infarction mortality[48-50]. For this reason, 
cardiovascular autonomic function testing is advisable 
for all diabetic patients after a myocardial infarction to 
identify the candidates who have a high risk of  death[51]. 
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functional myocardial abnormalities without coronary 
artery disease, hypertension or valvular heart disease[68]. It 
is characterized by diastolic dysfunction[69]. The responsible 
mechanisms are left ventricular hypertrophy (increased 
left ventricular mass and concentric remodeling[70]), 
myocardial lipotoxicity, increased oxidative stress, cell 
death, interstitial and perivascular fibrosis, impaired 
contractile reserve, changes in myocardial substrate and 
energy metabolism, altered substrate utilization and 
mitochondrial dysfunction[69]. In patients with CAN, 
the initial augmentation in cardiac sympathetic activity 
stimulates the renin-angiotensin-aldosterone system and 
increases heart rate, stroke volume and peripheral vascular 
resistance[71]. In addition, the combination of  sympathetic 
hyperactivity and regional myocardial sympathetic 
denervation cause reduced coronary blood flow and 
diastolic dysfunction, which may lead to impairment of  
systolic function[2]. 
Stroke
Previous studies have revealed the relationship between 
CAN and cerebrovascular events. Ko et al[72] reported 
that the presence of  CAN, assessed by HRV testing, 
was significantly associated with the ischemic stroke 
in a study of  1458 patients with type 2 diabetes with a 
7-year follow-up[72]. Another study of  133 subjects with 
type 2 diabetes showed that stroke could be predicted by 
parasympathetic and sympathetic autonomic function 
abnormalities[73].
DIAGNOSTIC METHODS OF CARDIAC 
AUTONOMIC NEUROPATHY
Variability in heart rate and blood pressure values can 
provide data regarding both parasympathetic and 
sympathetic autonomic function and is useful in clinical 
settings. 
Heart rate variability
The most commonly used methods for the diagnosis 
of  CAN are based on HRV assessment. HRV testing is 
noninvasive and objective in the evaluation of  cardiac 
autonomic function and can be performed by recording 
electrocardiograms during deep breathing, standing, 
and Valsalva maneuvers[74]. HRV analysis enables the 
independent measurement of  the sympathetic and 
parasympathetic components of  the autonomic nervous 
system and can be assessed with a number of  simple 
clinical tests[75] or easier digital 24-h electrocardiographic 
recordings[24].  In the 1970s, Ewing et al[75] discovered 5 
simple tests of  short-term R-R alterations to identify 
CAN in patients with diabetes: (1) heart rate response 
to respiration, which measures beat to beat sinus 
arrhythmia (R-R variation) during paced deep expiration 
and inspiration (E:I ratio); (2) heart rate response to 
standing, known as the 30:15 ratio, which is the ratio of  
the longest R-R interval (between beats 20 to 40) to the 
shortest R-R interval (between beats 5 to 25); (3) the 
Valsalva maneuver, measuring the heart rate response 
during and after a provoked increase in intra-thoracic and 
intra-abdominal pressures; (4) blood pressure response 
to orthostasis, which evaluates baroreflex mediated blood 
pressure fluctuations after changes in posture; and (5) 
blood pressure response to isometric exercise, as defined 
by the diastolic blood pressure increase due to continuous 
muscle contraction using a handgrip dynamometer[75]. 
Tests 1 and 2 reflect parasympathetic function, and 4 and 
5, sympathetic function[76,77]. Although the Valsalva ratio 
primarily represents parasympathetic activity, the resultant 
autonomic changes are complicated and include both 
the sympathetic and parasympathetic components[78]. An 
American Diabetes Association statement describes these 
validated cardiac autonomic reflex tests (CART) in detail 
and recommends their use in the diagnosis of  CAN (Table 
1)[1]. HRV with deep breathing is the most commonly 
used autonomic function test and has a specificity of  
approximately 80%[79,80]. 
The assessment of  HRV has become easier and more 
detailed due to new, digital, high frequency, 24-h multi-
channel electrocardiographic recorders and the use of  
statistical indexes in the time and frequency domains. 
Time domain methods
Time domain methods determine the heart rate at any 
point in time or the intervals between consecutive normal 
complexes[24]. Each QRS complex is detected and the 
normal-to-normal (NN) intervals (that is all intervals 
between adjacent QRS complexes resulting from sinus 
node depolarizations) or the instantaneous heart rate 
is determined through a continuous ECG record[24]. 
Simple time-domain variables that can be analyzed 
include mean NN interval, mean heart rate, the difference 
between the longest and the shortest NN interval and 
the variation between night and day heart rate[24]. More 
complex time-domain parameter calculations can be 
performed from a series of  instantaneous heart rates or 
cycle intervals, particularly those recorded during 24-h 
periods[24]. The complex parameters can be divided into 
2 classes: those derived from direct measurements of  
the NN intervals and those derived from the differences 
between NN intervals. The parameters calculated by 
direct measurements include: standard deviation of  the 
NN interval (SDNN), reflecting all cyclic components 
responsible for variability in the recording period; standard 
deviation of  the average NN interval (SDANN) calculated 
over periods (usually 5 min), estimating heart rate changes 
from cycles longer than 5 min; and the mean of  the 5-min 
standard deviation of  the NN interval (SDNN index) 
calculated over 24 h, measuring variability from cycles of  
less than 5 min. Secondly, the parameters calculated by 
the differences between NN intervals include the square 
root of  the mean squared differences of  successive NN 
intervals (RMSSD), the number of  interval differences of  
successive NN intervals of  more than 50 msec (NN50), 
and the division of  NN50 by the total number of  NN 
intervals (pNN50)[24]. Although influenced by several 
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arrhythmias and requiring normal sinus rhythm and 
atrioventricular nodal function, these short-term variation 
measurements estimate high frequency variations in 
heart rate and are therefore highly correlated[24]. SDNN 
represents both the sympathetic and parasympathetic 
modulation of  HRV, and RMSSD and pNN50 the 
parasympathetic system[24].
Frequency domain methods
CAN may also be evaluated using spectral analysis of  
HRV, which divides the R-R signal into sine and cosine 
waves to estimate the amount of  variability as a function 
of  frequency[24]. Three main spectral components are 
distinguished in a spectrum calculated from short-
term recordings of  2 to 5 min: very-low-frequency (≤ 
0.04 Hz) of  fluctuations in vasomotor tone related to 
thermoregulation, low-frequency (0.04-0.15 Hz) associated 
with the baroreceptor reflex, and high-frequency (0.15-0.4 
Hz) related to respiratory activity[24]. The sympathetic 
system is thought to modulate the 2 low-frequency 
components and the parasympathetic system the high-
frequency component[20]. Accordingly, while decreases in 
very-low- and low-frequency peaks indicate sympathetic 
dysfunction, a decrease in the high-frequency peak is a 
sign of  parasympathetic dysfunction[1]. A decrease in the 
ratio of  low-frequency-to-high-frequency demonstrates 
sympathetic imbalance[1]. Various mathematical methods 
can be used to analyze the spectral components of  
HRV. Most common is the Fourier transform because 
of  its simplicity and high processing speed[24]. A noise-
free signal is necessary in order to correctly perform 
the spectral analysis. Because artefacts and extra beats 
must be removed, this correction leads to data loss 
and is associated with an underestimation in each case. 
Additionally, specific reference values must be obtained 
as each HRV-analysing device has different technical 
properties for spectral measurements. 
It is not yet clear which of  these 2 methods is prefer-
able: time-domain methods including the standardized 
CART of  Ewing or frequency-domain methods. However, 
many time- and frequency-domain variables obtained 
over the 24-h period are highly correlated with each 
other[24]. On the other hand, studies comparing Holter-
based analysis and CART found a high (83%) correlation 
between the both techniques[81]. The advantages of  Holter-
based techniques include simpler, less stressful and faster 
implementation during daily routine use, independence 
of  patient cooperation and greater sensitivity allowing 
for the identification of  disorders in the early stages. 
However, CART can be applied quickly (less than 15 min) 
using stand-alone operator friendly devices during routine 
physical examination.
Heart rate turbulence
Another Holter-based technique for evaluating CAN 
is the heart rate turbulence (HRT)[82]. HRT refers to 
sinus rhythm cycle length fluctuations following isolated 
premature ventricular beats. After an initial acceleration, 
the sinus rate decelerates after a premature ventricular 
beat. There are 2 components of  HRT; turbulence onset 
and turbulence slope.  A transient vagal inhibition triggers 
the mentioned initial acceleration in heart rate as a 
response to the missed baroreflex afferent input due to 
hemodynamically ineffective ventricular contraction. 
The successive deceleration in heart rate is caused by a 
sympathetically mediated overshoot of  arterial pressure 
through vagal recruitment[82]. HRT evaluation can be used 
in the risk assessment after acute myocardial infarction 
and in the monitoring of  disease progression in heart 
failure and CAN[82]. We previously demonstrated that 
among HRV and HRT indexes, turbulence slope has the 
greatest correlation with CAN severity[83]. A turbulence 
slope of  below 3.32 msec/R-R is 97% sensitive and 71% 
specific for the diagnosis of  CAN as detected by the 
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Table 1  Cardiovascular autonomic reflex tests[1]
Test Technique Normal response and values
Beat-to-beat HRV With the patient at rest and supine, heart rate is monitored 
by ECG while the patient breathes in and out at 6 breaths per 
minute, paced by a metronome or similar device
A difference in heart rate of > 15 beats per minute is normal 
and < 10 beats per minute is abnormal. 
The lowest normal value for the expiration-to inspiration 
ratio of the R-R interval decreases with age: age 20-24 yr, 1.17; 
25-29, 1.15; 30-34, 1.13; 35-39, 1.12; 40-44, 1.10; 45-49, 1.08; 
50-54, 1.07; 55-59, 1.06; 60-64, 1.04; 65-69, 1.03; and 70-75, 1.02
Heart rate response to 
standing
During continuous ECG monitoring, the R-R interval is 
measured at beats 15 and 30 after standing 
Normally, a tachycardia is followed by reflex bradycardia. 
The 30:15 ratio should be > 1.03
Heart rate response to 
the Valsalva maneuver 
The subject forcibly exhales into the mouthpiece of a 
manometer to 40 mmHg for 15 s during ECG monitoring
Healthy subjects develop tachycardia and peripheral 
vasoconstriction during strain and an overshoot bradycardia 
and rise in blood pressure with release. The normal ratio of 
longest R-R to shortest R-R is > 1.2 
Systolic blood pressure 
response to standing
Systolic blood pressure is measured in the supine subject. The 
patient stands and the systolic blood pressure is measured 
after 2 min
Normal response is a fall of < 10 mmHg, borderline fall is a 
fall of 10-29 mmHg and abnormal fall is a decrease of > 30 
mmHg with symptoms
Diastolic blood pressure 
response to isometric 
exercise
The subject squeezes a handgrip dynamometer to establish a 
maximum. Grip is then squeezed at 30% maximum for 5 min
The normal response for diastolic blood pressure is a rise of 
> 16 mmHg in the other arm
HRV: Heart rate variability; ECG: Electrocardiogram.
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CART in patients with type 2 diabetes[83].  
Other diagnostic tools
Other methods currently used in research settings are 
scintigraphic evaluation of  sympathetic innervation of  
the heart, which can reveal cardiac sympathetic nerve 
population changes and early anatomical regional deficits 
of  sympathetic denervation[84-86]; microneurography, 
which records electrical activity released by peroneal, tibial 
or radial sympathetic nerves and identifies sympathetic 
dysfunction[87]; neurovascular flow, using noninvasive laser 
Doppler measures of  peripheral sympathetic reactions to 
nociception[88]; and baroreflex sensitivity, which evaluates 
the capability to reflexively increase vagal activity in 
response to a sudden increase in blood pressure[89]. As 
many of  these tests assess the influence on sympathetic 
component, they do not provide information about early 
stage CAN. In a recent study, it was shown that altered 
cardiac autonomic balance can be detected through 
exercise stress testing in diabetic subjects even with 
minimal evidence of  CAN[90]. 
Criteria for diagnosis and staging
CART are the gold standard clinical tests for cardio-
vascular autonomic neuropathy[91]. Following the 8th 
international symposium on diabetic neuropathy in 2010, 
criteria for diagnosis and staging of  CAN are defined 
in the CAN Subcommittee of  the Toronto Consensus 
Panel statement[92]. Accordingly, only 1 abnormal CART 
result is sufficient to diagnose possible or early CAN; 
among the 7 autonomic function analysis (5 CART, 
time-domain and frequency-domain HRV tests), 2 or 3 
abnormal tests indicate definite or confirmed CAN; and 
severe/advanced CAN can be indicated by concurrent 
orthostatic hypotension[91].
SCREENING FOR CAN
By the time clinical signs occur, CAN has often reached 
to a late stage, making management more difficult. 
Therefore, patients should be screened for CAN at the 
time of  diagnosis of  type 2 diabetes and within 5 years 
of  diagnosis of  type 1 diabetes (except presence of  
symptoms suggesting autonomic neuropathy earlier)[1]. 
In addition, screening may be of  benefit before under-
going an operation or beginning a new intense exercise 
program[93,94]. Screening should include a clinical history 
and an evaluation for evidence of  autonomic dys-
function. Main HRV tests (E:I ratio, heart rate response 
to Valsalva maneuver, and heart rate response to stan-
ding) should also be performed. As an alternative to 
CART, easier screening methods has been attempted 
to develop. For instance, sudomotor function tests that 
assess the cholinergic innervation of  sweat glands have 
been found to be useful for early screening of  CAN[95]. 
Ge et al[96] offered a new risk score system not requiring 
specific tests for screening CAN, using clinical parameters 
including age, body mass index, hypertension and resting 
heart rate. The risk score can be between 0 and 15, and 
a score of  6 can detect CAN in 72.87% of  previously 
undiagnosed individuals[96]. Screening should be repeated 
annually in the presence of  negative results[1]. 
THERAPEUTIC APPROACHES 
Early determination of  CAN is significant for the success 
of  therapeutic strategies as cardiovascular denervation 
seems to be reversible at onset[97]. In less affected patients, 
lifestyle changes including graded supervised exercise 
associated with weight loss improve HRV[97]. 
Optimizing glycemic control
Blood glucose optimization is the essential treatment 
for CAN. The Framingham Heart Study showed the 
significant association between reduced HRV and 
increased fasting plasma glucose level[98]. This finding is 
present in diabetics as well as individuals with impaired 
glucose tolerance[99]. Additionally, the DCCT reported 
that intensive insulin therapy reduced the incidence of  
CAN in comparison to conventional insulin therapy 
after approximately 5 years (14% vs 7%; P < 0.004) in 
type 1 diabetics[100]. The Epidemiology of  Diabetes 
Intervention and Complication Study (EDIC) is a 
longitudinal cohort follow-up study for the DCCT[101]. 
Pop-Busui et al[102] demonstrated that during EDIC 
follow-up, CAN progressed in both the conventional 
and intensive insulin therapy groups, while its incidence 
and prevalence remained lower in the intensive therapy 
group despite similar glycemic control[102]. Accordingly, 
the early initiation of  intensive glucose control in type 
1 diabetics can help to minimize the development of  
CAN[102]. On the other hand, the benefit of  glycemic 
control in type 2 diabetics is less certain[1,2]. The Veterans 
Affairs Cooperative Study reported a similar prevalence of  
autonomic neuropathy in type 2 diabetics after 2 years of  
intense glucose control in comparison with conventional 
glycemic control[103]. Similarly, in the Anglo-Danish-Dutch 
Study of  Intensive Treatment in People With Screen 
Detected Diabetes in Primary Care Danish arm, CAN 
was frequently found 6 years following diagnosis of  type 2 
diabetes and this prevalence was not significantly affected 
by intensive multifactorial treatment in comparison with 
routine care[104]. Conversely, in the Steno-2 Trial patients 
with type 2 diabetes were given intensive multifactorial 
treatment (e.g., targeting hyperglycemia, hypertension and 
dyslipidemia, including acetylsalicylic acid for secondary 
prevention) and targeted strict glycemic control as well 
as other cardiovascular risk factor modification, which 
reduced the incidence of  autonomic dysfunction by 
approximately 60%[105]. Briefly, the intensive blood 
glucose, HbA1c, blood pressure and lipid levels control 
using pharmacological therapy with lifestyle changes are 
recommended for all diabetic patients[1]. 
Other therapies
Functional disorders of  the autonomic nervous system 
can be treated with a variety of  medications. In a trial 
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including 73 type 2 diabetic subjects, a four-month period 
of  treatment with alpha-lipoic acid, which reduces oxygen 
free radicals, improved HRV detected by standardized 
CART[1,106]. While the use of  aldose reductase inhibitors 
(epalrestat, fidarestat and AS-3201), which reduce nerve 
sorbitol, had a positive influence on HRV in patients with 
mild abnormalities, they were ineffective in advanced 
CAN patients[1,107]. Total HRV has been shown to be 
increased and parasympathetic/sympathetic balance 
improved by angiotensin-converting enzyme (ACE) 
inhibition in patients with mild autonomic neuropathy 
through increases in nerve blood flow[1]. Prostoglandin 
analogs have been shown to be effective through the 
same mechanism[1]. Cardioselective beta-blockers are 
considered to have positive effects on autonomic 
dysfunction. For example, the addition of  metoprolol to 
ramipril therapy in patients with type 1 diabetes resulted 
in recovery of  HRV parameters[108]. Furthermore, 
bisoprolol improved HRV in heart failure[109]. In a study 
including individuals with long-term diabetes and diabetic 
neuropathy, the combination of  ACE inhibition and 
angiotensin-receptor blockade improved autonomic 
neuropathy[110]. In addition, Ozdemir et al[111] showed that 
losartan therapy significantly improved HRV in patients 
with ischemic cardiomyopathy already receiving ACE 
inhibitors and beta-blockers. Similarly, sympathovagal 
imbalance in heart failure patients was improved 
following the administration of  spironolactone along 
with enalapril, furosemide, and digoxin[112]. Such evidence 
reveals that combination therapies appear to provide 
better results than monotherapies.
Orthostatic hypotension 
Because orthostatic hypotension is a relatively late 
complication of  CAN, the treatment is challenging due 
to advanced disease. Nonpharmacological treatments 
include: increased water consumption; the use of  lower-
extremity stockings; avoidance of  sudden postural 
changes to standing up; avoidance of  medicines such 
as vasodilators, diuretics, phenothiazines and tricyclic 
antidepressants that provoke hypotension; eating frequent, 
small meals to prevent postprandial hypotension; and 
avoidance of  exercises and maneuvers that increase intra-
abdominal and intra-thoracic pressure resulting in venous 
return decrease[20]. Some physical preventive maneuvers, 
such as crossing of  the legs and squatting may counter 
decreases in blood pressure[9]. While pharmacological 
treatments, such as midodrine, clonidine, octreotide, 
fludrocortisone acetate, erythropoietin, nonselective beta-
blockers and prydostigmine bromide appear promising, all 
have mild to severe side effects, including hypertension[9]. 
CONCLUSION
Although very common and serious, CAN is a frequently 
overlooked complication of  diabetes. Related with 
intraoperative and perioperative cardiovascular instability, 
abnormal blood pressure profile, orthostatic hypotension, 
silent myocardial ischemia, arrhythmias, diabetic 
cardiomyopathy, and stroke, CAN is associated with 
significant increases in morbidity and mortality. Patients 
may have subclinical CAN for several years before it 
becomes clinically apparent. Because the progression of  
cardiovascular denervation is partly reversible or can be 
slowed down in the early stages of  the disease, recent 
guidelines strongly recommend screening for CAN in 
patients with diabetes. Assessment of  CAN is possible 
through a variety of  methods, such as CART, HRV and 
imaging modalities. Operator friendly devices and use 
of  Holter-based analysis has simplified CAN testing. 
Treatment principles include early diagnosis, optimization 
of  glycemic control, life style changes and management 
of  cardiovascular risk factors. Medical therapy, including 
aldose reductase inhibitors, ACE inhibitors, prostoglandin 
analogs and alpha-lipoic acid, have been found to be 
effective in randomized control trials for the treatment 
of  autonomic neuropathies. Orthostatic hypotension, 
which may lead to life-threatening injuries, is an undesired 
manifestation and indicates severe or advanced CAN. 
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